Stack Financial Management Inc decreased its position in Zoetis Inc (NYSE:ZTS) by 1.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 340,582 shares of the company’s stock after selling 4,446 shares during the period. Zoetis makes up 2.5% of Stack Financial Management Inc’s holdings, making the stock its 11th biggest holding. Stack Financial Management Inc owned about 0.07% of Zoetis worth $24,536,000 at the end of the most recent quarter.
A number of other hedge funds have also recently added to or reduced their stakes in ZTS. Northwestern Mutual Wealth Management Co. raised its holdings in shares of Zoetis by 16.8% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 1,598 shares of the company’s stock valued at $100,000 after purchasing an additional 230 shares during the period. Steward Partners Investment Advisory LLC acquired a new position in shares of Zoetis during the third quarter valued at about $114,000. Harfst & Associates Inc. raised its holdings in shares of Zoetis by 16.1% during the second quarter. Harfst & Associates Inc. now owns 1,878 shares of the company’s stock valued at $117,000 after purchasing an additional 260 shares during the period. Mitsubishi UFJ Securities Holdings Co. Ltd. raised its holdings in shares of Zoetis by 251.9% during the third quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 1,900 shares of the company’s stock valued at $121,000 after purchasing an additional 1,360 shares during the period. Finally, Shine Investment Advisory Services Inc. raised its holdings in shares of Zoetis by 86.5% during the third quarter. Shine Investment Advisory Services Inc. now owns 2,242 shares of the company’s stock valued at $143,000 after purchasing an additional 1,040 shares during the period. Institutional investors and hedge funds own 93.14% of the company’s stock.
Shares of Zoetis Inc (NYSE ZTS) opened at $76.62 on Monday. The company has a debt-to-equity ratio of 2.45, a current ratio of 2.80 and a quick ratio of 1.95. Zoetis Inc has a fifty-two week low of $52.00 and a fifty-two week high of $77.03. The firm has a market cap of $37,340.00, a PE ratio of 40.33, a P/E/G ratio of 1.83 and a beta of 1.06.
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 1st. Shareholders of record on Friday, January 19th will be given a $0.126 dividend. This represents a $0.50 dividend on an annualized basis and a yield of 0.66%. This is an increase from Zoetis’s previous quarterly dividend of $0.11. The ex-dividend date is Thursday, January 18th. Zoetis’s dividend payout ratio is presently 26.32%.
Several equities analysts have recently weighed in on the stock. Piper Jaffray Companies reiterated a “buy” rating and set a $86.00 price objective on shares of Zoetis in a report on Thursday. BMO Capital Markets upped their price objective on shares of Zoetis from $65.00 to $70.00 and gave the company a “market perform” rating in a report on Friday, November 3rd. BidaskClub lowered shares of Zoetis from a “buy” rating to a “hold” rating in a report on Thursday, October 26th. Cantor Fitzgerald reiterated a “buy” rating and set a $75.00 price objective on shares of Zoetis in a report on Tuesday, September 26th. Finally, Stifel Nicolaus reiterated a “buy” rating and set a $65.00 price objective on shares of Zoetis in a report on Tuesday, October 24th. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and fourteen have given a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $73.72.
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.